Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sustained attention

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Sustained attention. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-001217-27 Sponsor Protocol Number: CONCERTAATT4092 Start Date*: 2015-04-24
    Sponsor Name:Janssen Korea Ltd
    Full Title: An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children with ADHD (FOSCO)
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-004425-42 Sponsor Protocol Number: CHDR0723 Start Date*: 2008-09-15
    Sponsor Name:Centre for Human Drug Research
    Full Title: Neurocognitive testing in children with ADHD
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005056-96 Sponsor Protocol Number: TRAWADA2015 Start Date*: 2016-05-31
    Sponsor Name:Daniel Sanabria Lucena
    Full Title: Use of tramadol in healthy volunteers. Effects on physical performance and sustained attention in cycling.
    Medical condition: Sport doping
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10076471 Drug doping LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000821-29 Sponsor Protocol Number: SPD503-401 Start Date*: 2020-11-19
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...
    Medical condition: Attention-deficit/hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Trial now transitioned) SE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) PT (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003049-13 Sponsor Protocol Number: 7347 Start Date*: 2022-08-24
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: EEG-MRI study of the effect of methylphenidate on neural mechanisms in adult patients with ADHD with or without mood disorders: A randomized controlled trial versus placebo.
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003117-28 Sponsor Protocol Number: EPU-P77 Start Date*: 2014-11-03
    Sponsor Name:
    Full Title: Can Methylphenidate (Ritalin) improve memory and attention in mild cognitive impairment? An EEG study
    Medical condition: memory impairment in patients with Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10027174 Memory impaired LLT
    17.0 10029205 - Nervous system disorders 10027175 Memory impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001160-36 Sponsor Protocol Number: 2008-1 Start Date*: 2009-06-04
    Sponsor Name:Imperial College London
    Full Title: A trial of Guanfacine, an alpha 2 adrenergic agonist, for Spatial Neglect and Impaired Vigilance following Stroke and Focal Brain Damage
    Medical condition: Spatial Neglect following Hemispheric stroke and focal brain injury
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10050400 Vigilance decreased LLT
    14.0 10029205 - Nervous system disorders 10029289 Neurologic neglect syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002249-35 Sponsor Protocol Number: mkjf001 Start Date*: 2006-10-26
    Sponsor Name:Addiction Center Stockholm
    Full Title: Clinical trial of sustained release methylphenidate for Attention-Deficit-Hyperactivity-Disorder (ADHD) in adult criminal offenders with amphetamine addiction
    Medical condition: 54 male prison inmates (27 in each treatment condition) that meet the DSM-IV criteria for amphetamine addiction and for ADHD and who are servicing their prison sentence are recruited.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023992-24 Sponsor Protocol Number: MEMAP1 Start Date*: 2011-08-26
    Sponsor Name:University of Leipzig
    Full Title: International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate
    Medical condition: acute mania and hypomania (ICD-10: F30.0, F30.1, F31.0, F31.1)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10000852 Acute mania LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004466-14 Sponsor Protocol Number: RH01361 Start Date*: 2011-10-27
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: Effects of two doses of a common cold treatment on cognitive function
    Medical condition: Common cold
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10000938 Acute nasopharyngitis (common cold) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000388-10 Sponsor Protocol Number: WADA_17C09 Start Date*: 2019-06-11
    Sponsor Name:Daniel Sanabria
    Full Title: Clinical trial on the effects of the tramadol and paracetamol on physical, cognitive and brain performance during cycling
    Medical condition: Sports doping
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003956-30 Sponsor Protocol Number: CHDR1429 Start Date*: 2014-10-13
    Sponsor Name:Centre for Human Drug Research
    Full Title: A single-centre randomized double-blind, double-dummy, placebo-controlled, four-way crossover study in healthy subjects to investigate the effect of ethanol 0.5 and 1.0 g/L and alprazolam 1 mg on a...
    Medical condition: A total of 24 healthy subjects, both male and female, will be enrolled into the study following satisfactory completion of a screening visit where eligibility for the study will be checked. Subje...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001964-11 Sponsor Protocol Number: 2019/0411/HP Start Date*: 2021-12-17
    Sponsor Name:CHU de Rouen
    Full Title: Randomized double blind controlled trial comparing the safety and efficacy of apremilast versus placebo in severe forms of recurrent aphthous stomatitis
    Medical condition: Patients with severe forms of Recurrent Aphthous Stomatitis (RAS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10045372 Ulcers aphthous oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002598-36 Sponsor Protocol Number: 16IC3372 Start Date*: 2017-03-03
    Sponsor Name:Imperial College London
    Full Title: Randomised Clinical Trial of Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-001620-29 Sponsor Protocol Number: R2-GDP-GOTEL Start Date*: 2014-10-19
    Sponsor Name:Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)
    Full Title: Phase II clinical trial to evaluate the combination of lenalidomide with R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in patients diagnosed with refractory diffuse large B-cell lymph...
    Medical condition: Refractory Diffuse large B-cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001176-31 Sponsor Protocol Number: 19215 Start Date*: 2017-09-22
    Sponsor Name:Bayer AG,
    Full Title: BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies
    Medical condition: Clinically-isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) SE (Completed) GB (Completed) AT (Completed) CZ (Completed) FI (Completed) DK (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001254-17 Sponsor Protocol Number: CLCZ696B2320 Start Date*: 2016-09-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved e...
    Medical condition: Heart Failure with preserved ejection fraction (HF-pEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) DE (Completed) ES (Completed) BG (Completed) NL (Completed) PL (Completed) BE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003405-26 Sponsor Protocol Number: NF1-EXCEL Start Date*: 2014-09-03
    Sponsor Name:Erasmus MC
    Full Title: The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL)
    Medical condition: Neurofibromatosis type 1
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) DK (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004954-34 Sponsor Protocol Number: 28981 Start Date*: 2008-12-12
    Sponsor Name:Merck Serono S.A. - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin...
    Medical condition: Subjects of high risk of converting to Multiple Sclerosis or subjects already converted to Multiple Sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) FI (Completed) ES (Completed) PT (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) GR (Completed) IT (Completed) FR (Completed) BG (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001180-23 Sponsor Protocol Number: 1042-CDD-3001 Start Date*: 2018-12-06
    Sponsor Name:Marinus Pharmaceuticals, Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed b...
    Medical condition: Treatment of seizures in children and young adults with genetically confirmed cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10032062 Other forms of epilepsy, with intractable epilepsy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 12:06:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA